Long-Term Pharmacokinetics of Dalbavancin in ABSSSI and Osteoarticular Settings: A Real-Life Outpatient Context.
anti-infective
antibiotics
pharmacokinetics
pharmacokinetics-pharmacodynamics
quantitative pharmacology
Journal
Biomedicines
ISSN: 2227-9059
Titre abrégé: Biomedicines
Pays: Switzerland
ID NLM: 101691304
Informations de publication
Date de publication:
22 Sep 2021
22 Sep 2021
Historique:
received:
30
08
2021
revised:
16
09
2021
accepted:
17
09
2021
entrez:
23
10
2021
pubmed:
24
10
2021
medline:
24
10
2021
Statut:
epublish
Résumé
Dalbavancin is a lipoglycopeptide approved for treatment of Gram-positive infections of skin and skin-associated structures (ABSSSI). Currently, off-label use at high dosages for osteoarticular infections deserves attention. This work aimed to study the long-term plasma pharmacokinetics of dalbavancin in outpatients with ABSSSI or osteoarticular infections, treated either with one or two 1500 mg doses of dalbavancin. A liquid chromatography-tandem mass spectrometry method was used to measure total dalbavancin concentrations in plasma samples. The results were analyzed through a non-compartmental analysis (NCA). Breakpoint minimum inhibitory concentration (MIC) was used to calculate AUC/MIC and T > MIC parameters, adjusted by 93% protein binding. A total of 14 patients were enrolled, 11 with osteoarticular infection and 3 with ABSSSI. Long-term pharmacokinetics showed median T > MIC (0.125 mg/L) of 11.9 and 13.7 weeks for single and dual dose, respectively. Similarly, median AUC
Identifiants
pubmed: 34680409
pii: biomedicines9101288
doi: 10.3390/biomedicines9101288
pmc: PMC8533485
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Angelini Pharma
ID : Not Applicable, only publication fee coverage
Références
J Antimicrob Chemother. 2005 Mar;55 Suppl 2:ii31-5
pubmed: 15750035
N Engl J Med. 2014 Jun 5;370(23):2169-79
pubmed: 24897082
Antimicrob Agents Chemother. 2007 Aug;51(8):3008-10
pubmed: 17548492
Antimicrob Agents Chemother. 2007 May;51(5):1633-42
pubmed: 17307987
Int J Infect Dis. 2019 Apr;81:210-214
pubmed: 30794940
Diagn Microbiol Infect Dis. 2019 Mar;93(3):213-218
pubmed: 30396697
J Chromatogr B Analyt Technol Biomed Life Sci. 2011 Sep 1;879(25):2632-41
pubmed: 21831727
Antimicrob Agents Chemother. 2015 Aug;59(8):5007-9
pubmed: 25987636
J Antimicrob Chemother. 2016 Feb;71(2):460-3
pubmed: 26518048
J Antimicrob Chemother. 2005 Mar;55 Suppl 2:ii25-30
pubmed: 15750034
Clin Infect Dis. 2016 Mar 1;62(5):545-51
pubmed: 26611777
Diagn Microbiol Infect Dis. 2020 Feb;96(2):114901
pubmed: 31761480
Antimicrob Agents Chemother. 2021 Mar 1;:
pubmed: 33649108
Clin Ther. 2015 Dec 1;37(12):2619-36
pubmed: 26658277
J Clin Pharmacol. 2008 Sep;48(9):1063-8
pubmed: 18633123
Antimicrob Agents Chemother. 2004 Mar;48(3):940-5
pubmed: 14982787
Infect Dis (Lond). 2017 Jul;49(7):483-492
pubmed: 28264598
Int J Antimicrob Agents. 2019 Nov;54(5):668-672
pubmed: 31400471
Int J Infect Dis. 2019 Apr;81:128-136
pubmed: 30772469
Antimicrob Agents Chemother. 2005 Dec;49(12):5182-4
pubmed: 16304200
Am J Case Rep. 2017 Dec 09;18:1315-1319
pubmed: 29222405
Bioanalysis. 2017 Jul;9(14):1093-1105
pubmed: 28737421
Open Forum Infect Dis. 2018 Dec 10;6(1):ofy331
pubmed: 30648126
Antimicrob Agents Chemother. 2005 Feb;49(2):770-2
pubmed: 15673763
Front Microbiol. 2020 Apr 17;11:553
pubmed: 32362877
Antimicrob Agents Chemother. 2015 Apr;59(4):1849-55
pubmed: 25561338
Diagn Microbiol Infect Dis. 2015 May;82(1):73-7
pubmed: 25724854
Int J Antimicrob Agents. 2020 Sep;56(3):106069
pubmed: 32603683